Survodutide is a dual GLP-1/glucagon agonist from Boehringer Ingelheim. Where sema and tirz mainly hit appetite, survodutide's glucagon activation also goes after liver fat directly. Reducing hepatic fat, improving metabolic function, and addressing fibrosis. Phase 3 just landed: 16.6% weight loss at 76 weeks. It's also in trials for MASH (fatty liver disease), which is the real differentiator. The GI side effects are standard GLP-1 class stuff but at higher rates: 75% of participants reported GI events versus 42% on placebo.
Survodutide Protocol
Dose: Escalating: 0.3mg to 4.8mg weekly over ~17 weeks | Frequency: Once weekly subcutaneous injection | Cycle: Continuous. This is a pharmaceutical, not a cycle-on/off peptide | Route: SubQ
Reconstitution: Pre-filled pen in clinical trials. Research vials: follow concentration-specific instructions.. Free reconstitution calculator.
The escalation schedule is critical. Starting at full dose would be brutal GI-wise. The Phase 2 titration was: 0.3mg weeks 1-4, 0.9mg weeks 5-8, 1.8mg weeks 9-12, 2.7mg weeks 13-14, 3.6mg weeks 15-16, then 4.8mg from week 17 onward. Do not skip steps.
Survodutide Effects
Weight loss (85%). 16.6% body weight loss at 76 weeks in Phase 3 (~39 lbs average).
Appetite suppression (80%). The GLP-1 side kills your appetite and makes you feel full faster. Same mechanism as Ozempic.
Hepatic fat reduction (65%). The glucagon component directly reduces liver fat. This is what differentiates survodutide from pure GLP-1 drugs.
Metabolic improvement (60%). Blood sugar, inflammation, and liver scarring numbers all trend the right direction. The liver data is what has pharma analysts losing their minds.
Survodutide Side Effects
Nausea (45%). Hits hardest every time you bump the dose up. Subsides after a couple weeks at each level. The escalation schedule exists for a reason.
Vomiting (20%). Mostly during dose escalation phases. Temporary but not fun. Don't rush the titration.
Diarrhea (25%). Your gut motility is changing. Mild to moderate for most people. Hydrate.
Constipation (15%). Some people get the opposite GI effect. Bodies are unpredictable like that.
Survodutide Dosing by Use Case
Condition
Dose
Duration
Notes
Weight loss
Escalating: 0.3mg to 4.8mg weekly over 17 weeks
Continuous
Phase 3 SYNCHRONIZE-1 hit both co-primary endpoints: 16.6% body weight loss at 76 weeks vs 3.2% on placebo. That's about 39 lbs average. The glucagon receptor adds thermogenic fat burning on top of GLP-1 appetite suppression. The escalation schedule is critical. Don't skip steps.
Fatty liver disease (MASH)
Escalating to 4.8mg weekly
Ongoing
The real differentiator. Phase 2 NEJM data (Sanyal et al. 2024) showed dramatic liver fat reduction and fibrosis improvement. The glucagon component drives liver fat burning directly. Semaglutide reduces liver fat indirectly through weight loss. Survodutide attacks it from both sides.
After semaglutide plateau
Start at 0.3mg, titrate independently
Continuous
If you've plateaued on semaglutide (GLP-1 only), survodutide adds the glucagon receptor for thermogenic fat burning. Different enough mechanism to potentially break through a set point. Start the escalation from scratch regardless of prior GLP-1 dose.
Survodutide Results Timeline
Week 1-4, 0.3mg, tolerance building: Minimal weight loss at the starting dose. GI side effects are mild. This phase exists so your gut adjusts before the higher doses hit.
Week 5-12, 0.9-1.8mg, appetite shifting: Appetite suppression becomes noticeable. Weight loss begins. GI side effects peak with each dose increase and settle within 1-2 weeks. 2-4% body weight loss typical by week 12.
Week 12-24, 2.7-4.8mg, peak weight loss: Fastest rate of weight loss. The dual mechanism is in full effect: GLP-1 suppressing appetite + glucagon burning liver fat. GI side effects are real at these doses. 75% of participants reported GI events vs 42% on placebo.
Week 24+, Maintenance: Weight loss decelerates toward a new equilibrium. The Phase 3 endpoint was 76 weeks. Liver fat and metabolic markers continue improving. No published data on weight regain after stopping, but expect similar dynamics to other GLP-1 class drugs.
Frequently Asked Questions About Survodutide
What is survodutide?
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim. It works through two pathways: GLP-1 suppresses appetite and improves insulin sensitivity, glucagon increases energy expenditure and burns liver fat directly. Phase 3 (SYNCHRONIZE-1) showed 16.6% body weight loss at 76 weeks. Separate Phase 2 trials for MASH (fatty liver disease) showed significant liver fat reduction and fibrosis improvement.
Survodutide vs tirzepatide: what's the difference?
Different receptor combinations. Tirzepatide hits GLP-1 + GIP (two receptors). Survodutide hits GLP-1 + glucagon (different two receptors). Tirzepatide produced 22.5% weight loss in SURMOUNT-1. Survodutide produced 16.6% in SYNCHRONIZE-1. But survodutide's glucagon component burns liver fat directly more aggressively. If your primary concern is liver fat or MASH, survodutide's mechanism is more targeted for that.
What are the side effects of survodutide?
Nausea (45%), diarrhea (25%), vomiting (20%), constipation (15%). 75% of participants in the Phase 3 trial reported at least one GI event vs 42% on placebo. These rates are higher than semaglutide but comparable to retatrutide at similar efficacy doses. The escalation schedule exists to manage this. Rushing it makes the GI effects much worse.
Is survodutide FDA-approved?
No. As of September 2026, survodutide is in Phase 3 trials for obesity (SYNCHRONIZE program) and Phase 2 for MASH. Boehringer Ingelheim is the developer. FDA submission is expected based on SYNCHRONIZE-1 results, but approval has not been granted yet.
What is the survodutide dosage schedule?
Escalating: 0.3mg weeks 1-4, 0.9mg weeks 5-8, 1.8mg weeks 9-12, 2.7mg weeks 13-14, 3.6mg weeks 15-16, 4.8mg from week 17 onward. Once weekly SubQ. Do not skip the escalation steps. Each dose level needs 2-4 weeks to allow GI adaptation before increasing.
How do you reconstitute survodutide?
Clinical trials used pre-filled pens. Research vials vary by concentration. Follow the specific concentration listed on your vial label. Calculate your dose in units based on mg/mL concentration. Use our calculator for exact unit conversion. Inject subcutaneously once weekly. Refrigerate after reconstitution.
Evidence
Emerging evidence. Phase 3 SYNCHRONIZE-1 trial (April 2026) hit both co-primary endpoints: 16.6% body weight loss at 76 weeks versus 3.2% on placebo. That's roughly 39 lbs average. Phase 2 showed up to 19% weight loss at 46 weeks. Boehringer Ingelheim is pushing this hard as a dual GLP-1/glucagon agonist (meaning it activates both receptors at once) with liver benefits the pure GLP-1 drugs don't have.
Approval status: Phase 3 trials ongoing. Not yet approved.
References
le Roux CW et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial Lancet Diabetes Endocrinol, 2024. PMID 38330987
Sanyal AJ et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis N Engl J Med, 2024. PMID 38847460
Blüher M et al. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial Diabetologia, 2024. PMID 38095657
Wharton S et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2) Obesity (Silver Spring), 2025. PMID 39495965
le Roux CW et al. Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1) Diabetes Obes Metab, 2026. PMID 41187967
Storage
Lyophilized: Refrigerate 2-8C. Do not freeze. Keep in original packaging to protect from light.
Reconstituted: Refrigerate at 2-8C. Use within 4 weeks. Pre-filled pens follow manufacturer storage guidance.
Water: Clinical formulation is pre-mixed. Research vials use bacteriostatic water per manufacturer specs.
These statements have not been evaluated by the FDA. This content is for educational purposes only. Consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.
